 |
71 Diseases |  |
138 Trials |
|
138 Trials |  |
3168 News |  |
| 12345678910111213...4344» |
- ||||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion, Monotherapy: OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov) - Feb 14, 2026
P3, N=302, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed
- | SYS6010 / CSPC Pharma
New P3 trial: A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Feb 13, 2026
P3, N=400, Not yet recruiting, Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
- | Halaven (eribulin mesylate) / Eisai
Journal: Eribulin-induced resolution of high-risk basal cell carcinoma: implications for microtubule-targeting agents in BCC management: a case report. (Pubmed Central) - Feb 3, 2026
Active, not recruiting --> Completed No abstract available
- | Journal: ZSTK3744, a novel aryl hydrocarbon receptor agonist, exhibits efficacy against chemotherapy-resistant triple-negative breast cancer. (Pubmed Central) - Feb 2, 2026
These results suggest that ZSTK3744 combines robust cell growth-inhibitory activity with a favorable safety profile. In conclusion, ZSTK3744 is a promising candidate for overcoming chemotherapy resistance in TNBC, addressing the urgent need for more effective treatment options for this aggressive cancer subtype.
- | Halaven (eribulin mesylate) / Eisai
Biomarker, Retrospective data, Journal: Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective study. (Pubmed Central) - Jan 31, 2026
An ALC???1000/?L at ERI completion was associated with an improved post-ERI OS (OS2). It is suggested that not only the factors at the initiation of ERI, but also the immunological status at the end of ERI, may have prognostic value after ERI.
- | Puyouheng (pucotenlimab) / Taizhou Hanzhong Biopharma, Lepu Med, Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: Pucotenlimab Combined with Lenvatinib and eribulin in Patients with Advanced Melanoma Failed in First-Line Therapy, a Single-Arm, Open-Label, Multicenter, Phase II Clinical Study (EUDRACT) - Jan 31, 2026
P=N/A, N=35, Not yet recruiting, Sponsor: Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
- | Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P3 trial: Doxorubicin alone versus eribulin with anlotinib followed by anlotinib alone as first-line therapy for metastatic or unresectable L-type sarcoma: a randomised, multicentre,open-label phase 3 trial (EUDRACT) - Jan 31, 2026
P3, N=120, Not yet recruiting, Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University
- | Halaven (eribulin mesylate) / Eisai, Yidafan (ivonescimab) / Summit Therapeutics
New P2 trial: A Single-Arm, Multicenter Clinical Study of Eribulin Mesylate in Combination with Ivonescimab as First-Line Treatment for Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (EUDRACT) - Jan 31, 2026
P2, N=50, Not yet recruiting, Sponsor: Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
- | Puyouheng (pucotenlimab) / Taizhou Hanzhong Biopharma, Lepu Med, Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Pucotenlimab Combined with Lenvatinib and eribulin in Patients with Advanced Sarcoma Failed in First-Line Therapy, a Single-Arm, Open-Label, Multicenter, Phase II Clinical Study (EUDRACT) - Jan 31, 2026
P2, N=33, Not yet recruiting, Sponsor: Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
- | Halaven (eribulin mesylate) / Eisai, capecitabine / Generic mfg.
Journal: Clinical complete response achieved in patients with breast cancer liver metastasis after personalized treatment: a case report and literature review. (Pubmed Central) - Jan 28, 2026
Here, we first reported a case of breast cancer liver metastasis that obtained clinical complete response (cCR) after treatment with eribulin and capecitabine, which showed sensitivity in the organoid drug sensitivity testing, and we conducted a systematic literature review. Our case report further provides a scientific basis for the PDOs as a powerful preclinical model to predict individual treatment sensitivity and improve the treatment outcomes of patients with advanced breast cancer, especially those with refractory or heavily treated breast cancer.
- | Halaven (eribulin mesylate) / Eisai, Neulasta (pegfilgrastim) / Roche
Clinical data, Retrospective data, Journal: Clinical outcome of 50 patients treated with eribulin for soft tissue sarcoma: a single-institute retrospective study. (Pubmed Central) - Jan 25, 2026
Although no significant prognostic factors were identified, bi-weekly dosing and two-administration/2-week rest schedules were feasible, with the latter offering the advantage of pegfilgrastim support. These findings support the integration of eribulin into individualized treatment strategies for advanced STS and highlight the need for prospective studies to refine patient selection and optimize dosing approaches.
- | Halaven (eribulin mesylate) / Eisai
Journal: A Japanese Multicenter Database Study of Retroperitoneal Sarcoma: Outcomes of Patients Receiving Eribulin Therapy. (Pubmed Central) - Jan 22, 2026
We separately described outcomes and treatment patterns of patients with resectable and unresectable RPS. Our findings suggest that eribulin should be considered a treatment option for unresectable RPS in clinical practice.
- Halaven (eribulin mesylate) / Eisai
A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 (Poster Board No.M22; Level 1, West Hall) - Jan 20, 2026 - Abstract #ASCOGU2026ASCO_GU_772;
P3
Clinical Trial Registry Number: NCT04579224. The full, final text of this abstract will be available on Feb 23 at 05:00 PM EST.
- | Halaven (eribulin mesylate) / Eisai
Journal: Primary Dedifferentiated Liposarcoma of the Duodenum with Intestinal Bleeding: A Case Report and Literature Review. (Pubmed Central) - Jan 18, 2026
She received palliative radiotherapy to control bleeding, followed by eribulin-based chemotherapy, which temporarily shrank the tumor and allowed discontinuation of parenteral nutrition...The patient died nine months after the diagnosis. This rare case highlights the challenges of managing unresectable primary duodenal dedifferentiated liposarcoma but suggests that radiotherapy and systemic therapy can provide temporary control and symptom relief.
- | Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Halaven (eribulin mesylate) / Eisai, BB-1701 / BlissBio
Journal: Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers. (Pubmed Central) - Jan 18, 2026
This rare case highlights the challenges of managing unresectable primary duodenal dedifferentiated liposarcoma but suggests that radiotherapy and systemic therapy can provide temporary control and symptom relief. Moreover, BB-1701, a novel HER2-ADC containing eribulin as a payload, to which N87 AR cells are sensitive, exhibited antitumor effects in N87 AR cells in
- | Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Halaven (eribulin mesylate) / Eisai, Nerlynx (neratinib) / Puma
New P2 trial: NETHER: Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer (clinicaltrials.gov) - Jan 12, 2026
P2, N=35, Not yet recruiting, Sponsor: Xijing Hospital
- || Halaven (eribulin mesylate) / Eisai
P2 data, Journal: A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE). (Pubmed Central) - Jan 2, 2026
Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity.
- | Review, Journal: The Role of Natural Product Chemistry in Drug Discovery: Two Decades of Progress and Perspectives. (Pubmed Central) - Dec 26, 2025
While growth is modest, NPs remain highly valuable active pharmaceutical ingredients (APIs) with substantial clinical impact. Significant opportunities persist for drug-focused NP R&D efforts, as many recently validated therapeutic targets remain underexplored for NP-D chemotypes.
- | Journal: Monitoring of occupational exposure to hazardous medicinal products in robotic compounding. (Pubmed Central) - Dec 23, 2025
Occupational exposure to HMPs remains consistently below 0.1 ng/cm2, a threshold deemed safe according to various studies. These findings assure the safety of compounding personnel and other hospital staff involved in cancer treatment.
- || Halaven (eribulin mesylate) / Eisai, farletuzumab ecteribulin (MORAb-202) / Eisai
P1 data, Journal, Platinum resistant: Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: Phase I expansion results. (Pubmed Central) - Dec 23, 2025
P1
These findings assure the safety of compounding personnel and other hospital staff involved in cancer treatment. FZEC showed promising antitumor activity, and the observed adverse events were generally manageable, with the exception of ILD, in patients with PROC.
- Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD), farletuzumab ecteribulin (MORAb-202) / Eisai
Open label, multicenter, phase 2 study of farletuzumab ecteribulin, a folate receptor alpha-targeting antibody-drug conjugate, alone and in combination with lenvatinib in platinum-resistant ovarian cancer (Poster Area, Bella Centre, Exhibition hall (D5)) - Dec 23, 2025 - Abstract #ESGO2026ESGO_1275;
- | Journal: Eribulin and sintilimab combined with radiotherapy in a heavily pretreated patient with advanced retroperitoneal myxoid pleomorphic liposarcoma: a case report and literature review. (Pubmed Central) - Dec 22, 2025
Following this, she received gemcitabine plus albumin paclitaxel as second-line therapy...The demonstrated effectiveness of this multidisciplinary approach underscores its potential as a novel treatment strategy for patients with advanced MPLPS. To our knowledge, this article represents the first detailed documentation of multidisciplinary diagnosis and treatment of MPLPS.
- | Halaven (eribulin mesylate) / Eisai, Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) - Dec 16, 2025
P2, N=37, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
To our knowledge, this article represents the first detailed documentation of multidisciplinary diagnosis and treatment of MPLPS. Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
- | EP-101 STEMVAC / EpiThany, University of Washington
Trial initiation date: A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Dec 15, 2025
P2, N=20, Not yet recruiting, Sponsor: University of Washington
Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027 Initiation date: Dec 2025 --> Mar 2026
- | Halaven (eribulin mesylate) / Eisai
Journal: Combining anti-metabolic treatments with the repurposing of eribulin for glioblastoma: a clinical opportunity? (Pubmed Central) - Dec 11, 2025
Initiation date: Dec 2025 --> Mar 2026 No abstract available
- | Halaven (eribulin mesylate) / Eisai
Review, Journal: Epithelial-mesenchymal dynamics in cancer: Role of signalling pathways, stromal interactions and natural therapies. (Pubmed Central) - Dec 1, 2025
Furthermore, marine-based compounds, including caprolactin C, laminaran sulfate, BFP-3, bryostatin 1, sinulariolide, manzamines, halichondrin B, eribulin and biemamides, exhibit significant anti-metastatic effects by targeting EMT-associated pathways. The diverse range of therapeutic molecules discussed in this review provides promising therapeutic avenues for developing targeted strategies against EMT in cancer.
- || Halaven (eribulin mesylate) / Eisai
P2 data, Journal: A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701). (Pubmed Central) - Nov 30, 2025
This phase II study of eribulin for patients with BRAF V600E mutant mCRC did not meet the primary endpoint. Although BM2 on gene expression analysis of BM subtype may be a predictive marker of eribulin efficacy, further studies are required to validate this hypothesis.
- | Biomarker, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Pathological complete response to pembrolizumab in recurrent retroperitoneal dedifferentiated liposarcoma with high tumor mutational burden: a case report. (Pubmed Central) - Nov 29, 2025
This is the first reported case of recurrent retroperitoneal DDLPS with high TMB achieving pCR to pembrolizumab. High TMB and high TAM density in the tumor microenvironment may be predictive biomarkers for the response to ICIs in DDLPS.
- ||| Enrollment change, Trial completion date, Trial primary completion date: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Nov 28, 2025
P1/2, N=792, Recruiting, Sponsor: Hoffmann-La Roche
High TMB and high TAM density in the tumor microenvironment may be predictive biomarkers for the response to ICIs in DDLPS. N=580 --> 792 | Trial completion date: May 2028 --> Sep 2030 | Trial primary completion date: May 2028 --> Sep 2030
- | Halaven (eribulin mesylate) / Eisai
Journal: Improved biodistribution and antitumor effects of a Nectin4 and Trop2 bispecific fatty acid-modified nanobody conjugate. (Pubmed Central) - Nov 27, 2025
In nonclinical evaluations, Eribulin-loaded dtNDC demonstrated potent antitumor efficacy across three xenograft models...These findings position dtNDC as a promising therapeutic combining durable tumor regression with exceptional tolerability. Moreover, its simplified structure and cost-effective manufacturing process make this dtNDC a compelling next-generation therapeutic for cancers.
- |||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial primary completion date: DESTINY Breast Respond HER2-low Europe (clinicaltrials.gov) - Nov 18, 2025
P=N/A, N=1155, Recruiting, Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Moreover, its simplified structure and cost-effective manufacturing process make this dtNDC a compelling next-generation therapeutic for cancers. Trial primary completion date: Jun 2027 --> Sep 2028
- |||||| pumitamig (BNT327) / BioNTech, BMS
Enrollment open: ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (clinicaltrials.gov) - Nov 14, 2025
P3, N=558, Recruiting, Sponsor: BioNTech SE
Trial primary completion date: Jun 2027 --> Sep 2028 Not yet recruiting --> Recruiting
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Halaven (eribulin mesylate) / Eisai
Journal: Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer. (Pubmed Central) - Nov 12, 2025
Outcomes of post-T-DXd treatments differ significantly by MBC subtype and type of regimen administered. The use of SG immediately after T-DXd was associated with relatively short rwPFS across subtypes, highlighting some degree of cross-resistance with T-DXd.
- | Halaven (eribulin mesylate) / Eisai
Phase classification: A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Nov 11, 2025
P1, N=48, Recruiting, Sponsor: M.D. Anderson Cancer Center
The use of SG immediately after T-DXd was associated with relatively short rwPFS across subtypes, highlighting some degree of cross-resistance with T-DXd. Phase classification: P1/2 --> P1
- pumitamig (BNT327) / BioNTech, BMS
Preliminary data from a global multicohort Phase2 randomized trial of pumitamig (PD-L1 (Exhibit Hall) - Nov 10, 2025 - Abstract #SABCS2025SABCS_2447;
P2, P3
The efficacy is particularly clinically meaningful in pts with CPS <10, addressing a critical unmet need. No new safety signals were seen compared to previously characterized safety profile of pumitamig.
- Datroway (datopotamab deruxtecan-dlnk) / Daiichi Sankyo, AstraZeneca
Economic Impact of Adverse Event Management in HR+/HER2? Metastatic Breast Cancer: A Comparative Analysis of Datopotamab deruxtecan and standard of care in the Brazilian Private Healthcare System (Exhibit Hall) - Nov 10, 2025 - Abstract #SABCS2025SABCS_2420;
Dato-DXd demonstrated lower expenditures associated with adverse event management compared to its respective ICC arm comparator. SG was associated with higher AE-related costs relative to its respective ICC arm comparator.
- Chronification of metastatic leiomyosarcoma in 9 lines of therapy by precision oncology: A case report (X / Y (Confex)) - Nov 5, 2025 - Abstract #DGHO2025DGHO_1259;
The identified HRR deficiency enabled targeted PARP inhibition with clinically meaningful disease control. The combination of olaparib and temozolomide may represent a promising treatment option not only in uterine LMS, but also in non-uterine LMS with HRR deficiency.
- Halaven (eribulin mesylate) / Eisai
Efficacy and Safety of Eribulin in Liposarcoma and Leiomyosarcoma: A Systematic Review and Meta-Analysis (X / Y (Confex)) - Nov 5, 2025 - Abstract #DGHO2025DGHO_488;
The combination of olaparib and temozolomide may represent a promising treatment option not only in uterine LMS, but also in non-uterine LMS with HRR deficiency. Eribulin improves survival in liposarcoma and leiomyosarcoma with a manageable safety profile, highlighting its value as an effective treatment and the need for further research to optimize its clinical use
- || Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal: An open-label phase II study: The efficiency and safety of anlotinib?+?eribulin in patients with HER2-negative metastatic breast cancer. (Pubmed Central) - Nov 5, 2025
P2
The most common treatment-related adverse events (TRAEs) were neutropenia (67.14%) and leukopenia (68.57%), with 41.43% and 27.14% of patients experiencing grade 3/4 hematologic toxicities, respectively. These findings suggest that the combination of eribulin and anlotinib demonstrated encouraging efficacy and a manageable safety profile, offering a potential therapeutic option for patients with HER2-negative mBC.
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Halaven (eribulin mesylate) / Eisai, doxorubicin hydrochloride / Generic mfg.
Journal: Targeting Interleukin-6 as a Novel Strategy to Overcome Eribulin Resistance in Breast Cancer. (Pubmed Central) - Nov 5, 2025
These findings suggest that the combination of eribulin and anlotinib demonstrated encouraging efficacy and a manageable safety profile, offering a potential therapeutic option for patients with HER2-negative mBC. These findings suggest that IL-6 contributes to eribulin resistance in breast cancer and that IL-6 receptor inhibition is a promising therapeutic strategy to overcome this resistance.
- |||| Datroway (datopotamab deruxtecan-dlnk) / Daiichi Sankyo, AstraZeneca
Trial primary completion date: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) (clinicaltrials.gov) - Nov 4, 2025
P3, N=644, Active, not recruiting, Sponsor: AstraZeneca
These findings suggest that IL-6 contributes to eribulin resistance in breast cancer and that IL-6 receptor inhibition is a promising therapeutic strategy to overcome this resistance. Trial primary completion date: Dec 2025 --> Aug 2025
- | Halaven (eribulin mesylate) / Eisai
Journal: Prognostic significance of baseline skeletal muscle index and its dynamics in patients with metastatic breast cancer undergoing eribulin treatment. (Pubmed Central) - Nov 3, 2025
Furthermore, on-treatment SMI gain, but not PNI increase, was associated with improved survival. Monitoring and enhancing skeletal muscle mass may improve outcomes, highlighting the importance of integrating supportive care strategies during chemotherapy.
- || Halaven (eribulin mesylate) / Eisai
P4 data, Retrospective data, Journal: Prognosis of Invasive Lobular Carcinoma and Effectiveness of Eribulin in Clinical Practice: A Post Hoc Analysis of a 2-Year Post-Marketing Surveillance. (Pubmed Central) - Nov 3, 2025
P=N/A
Monitoring and enhancing skeletal muscle mass may improve outcomes, highlighting the importance of integrating supportive care strategies during chemotherapy. OS and TTF after eribulin initiation were similar between ILC and IDC cases, suggesting that eribulin might be a beneficial treatment option for ILC.
- | Halaven (eribulin mesylate) / Eisai
New P4 trial: Efficacy and Safety of Epalolitovorellizumab in Combination with Eribulin as Second-line and Later-line Therapy for Patients with Advanced Triple-negative Breast Cancer (EUDRACT) - Oct 31, 2025
P4, N=49, Not yet recruiting, Sponsor: Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital
- pumitamig (BNT327) / BioNTech, BMS
A global Phase III, randomized, double-blind trial of BNT327 plus chemotherapy (chemo) vs placebo plus chemo in patients (pts) with previously untreated locally recurrent inoperable or metastatic, PD-L1 negative triple negative breast cancer (TNBC) (ROSETTA Breast-01) (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_2181;
P1/2
OS and TTF after eribulin initiation were similar between ILC and IDC cases, suggesting that eribulin might be a beneficial treatment option for ILC. Pts are stratified by prior treatment with cancer immunotherapy in the neoadjuvant/adjuvant setting, on-trial chemo regimen, and geography, and randomized 1:1 to receive a combination treatment with BNT327 or placebo plus physician
- Xtandi (enzalutamide) / Pfizer, Astellas, Mifeprex (mifepristone) / Danco Laboratories
Tbcrc 058: a randomized phase 2 study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (nct06099769) (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_2167;
P2
As of 7/9/2025, 19 of 201 pts have begun protocol-specified tx. This trial is supported by the Translational Breast Cancer Research Consortium, The Breast Cancer Research Foundation, The TaTa Sisterhood Foundation, Pfizer/Astellas, and Corcept Therapeutics.
- evexomostat (SDX-7320) / SynDevRx, Halaven (eribulin mesylate) / Eisai
Aretha trial: Safety run-in results of eribulin + evexomostat in metastatic triple-negative breast cancer with metabolic dysfunction (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1991;
P2
Evexomostat + eribulin safety was confirmed and the trial advanced to the randomization phase including a placebo-controlled arm with eribulin. Preliminary biomarker results indicate that insulin resistance was unchanged, and favorable changes were seen in other metabolic markers.
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Jbcrg-m06/emerald post-hoc analysis by physician's choice of docetaxel or paclitaxel: efficacy and safety of eribulin mesylate vs taxanes combined with trastuzumab and pertuzumab as first-line for her2-positive locally advanced or metastatic breast cancer (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1945;
P3
No differences in efficacy (i.e. non-inferiority results) were observed based on type of T used. While AEs were generally similar between the E and T groups, regardless of type of T used, a higher incidence of peripheral sensory neuropathy was noted with PTX compared with E or DTX.
- Cytokine score based on expression levels of multiple cytokines is a prognostic indicator in metastatic breast cancer patients treated with chemotherapy (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1582;
The cytokine score, based on the number of elevated cytokines, is an important prognostic indicator for both OS and PFS. Furthermore, since a high cytokine score was associated with higher levels of MDSCs, and lower levels of CD4+ and CD8+ lymphocytes, the cytokine score might be associated with patient outcomes through immune reaction.
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
The Utility of MT1-MMP in Predicting Treatment Efficacy with HER2-positive advanced or metastatic breast cancer: JBCRG-M06/EMERALD trial TR (Exhibit Hall) - Oct 30, 2025 - Abstract #SABCS2025SABCS_1580;
The MT1-MMP score is unable to distinguish the combined trastuzumab and pertuzumab with eribulin mesylate or trastuzumab and pertuzumab with taxane therapy. However, it may be a prognostic factor for HER2-positive local advanced or metastatic breast cancer patients treated with the trastuzumab and pertuzumab combination and eribulin mesylate or taxane.